Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Clinical trial NCT04114136 · RECRUITING

Trial details

NCT number: NCT04114136
Sponsor: Dan Zandberg
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma NSCLC Hepatocellular Carcinoma Urothelial Cancer Gastric Adenocarcinoma HNSCC Esophageal Adenocarcinoma Microsatellite Instability-High Solid Malignant Tumor

Start date: 2020-09-14
Primary completion: 2032-04-30
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.